In summary, in this post hoc analysis, dapagliflozin, compared with placebo, reduced the incidence of investigator-reported (but not adjudicated) ventricular arrhythmias in patients with HFrEF, most of whom were treated with a renin–angiotensin system blocker, beta-blocker, and an MRA as well. This evidence concerns the gene REN and Ventricular arrhythmia.